Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Stellar Biotechnologies, Inc. (SBOTF) Details Compelling Business Model During Corporate Update Call

|Includes: Stellar Biotechnologies Inc. (SBOT)

Stellar Biotechnologies, the world leader in the development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH), provided investors with a complete overview of the company and initiatives underway. CEO Frank Oakes explained how the company stands out in the biotechnology industry as the only company dedicated solely to developing and commercializing KLH.

An important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets, KLH has a 40+ year track record of safe use in immunology. This protein has been used in hundreds of clinical trials. Most importantly, KLH has a number of high-value commercial pathways.

Eight years of R&D have been invested in Stellar's technology; funded by $7 million in NIH and NSF grants in addition to $23 million in equity funding. The company's multiple competitive advantages and strong head start put it far ahead of any potential competitor.

During one part of the call, Oaks showed investors a sample of the private companies, research institutions, and global pharma companies that are using KLH in active immune therapy trials. The extraordinary commercialization potential of this protein was further revealed by the possible annual revenues that could be generated from various indications such as rheumatoid arthritis ($200M), Alzheimer's ($200M), autoimmune diseases ($70-100M), infectious diseases ($100-150M), and others.

The question and answer session at the end of the call brought out even more exciting aspects to consider when evaluating Steller Biotechnologies as an investment. For instance, when responding to one investor's question, Oakes noted that Stellar benefits significantly from the fact that drug developers at large pharma and boutique pharma companies have been doing the heavy lifting by funding clinical trials that cost hundreds of millions of dollars to get drugs through clinical development to commercialization.

To learn more the significant milestones achieved in 2013 and the company's plans for expansion involving potential catalysts in R&D, manufacturing, and business development, view the recorded webcast at

For more information on Stellar Biotechnologies, visit

MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit